And that hold, I think, can be described as temporary, while we incorporate FDA's suggestions into our clinical protocol, get it back to them, give them another opportunity to review and comment, and then move forward. So I am, as I indicated, I'm very grateful to FDA. for the thoughtful comments and deep thinking they did about how CytoDyn should approach immune activation with leronlimab.